Form 4: Soleno Therapeutics CEO Anish Bhatnagar Sells Shares to Cover Tax Obligations

CEO of Soleno Therapeutics, Anish Bhatnagar, reports selling shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Anish Bhatnagar, CEO of Soleno Therapeutics, filed a Form 4 disclosing the sale of common stock.
• The sales occurred on August 28 and 29, 2024.
• The shares were sold to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
• On August 28, 2024, 30,262 shares were sold at a weighted average price of $47.1926, and 26,351 shares were sold at a weighted average price of $48.0274.
• On August 29, 2024, 47,551 shares were sold at a weighted average price of $47.1596, and 10,840 shares were sold at a weighted average price of $47.8329.
• Following these transactions, Bhatnagar still beneficially owns 741,186 shares of Soleno Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales for tax obligations, which is a routine event.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's perspective on the company's stock and future prospects.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the reason for the sale.

Key Dates